NasdaqGS - Nasdaq Real Time Price ? USD Ascendis Pharma A/S (ASND) Follow Compare 129.81 +7.17 (+5.85%) At close: 4:00 PM EST 129.81 0.00 (0.00%) After hours: 4:00 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Ascendis Pharma Reports Third Quarter 2024 Financial Results – YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3 – TransCon CNP NDA submission for achondroplasia planned for Q1 2025 followed by MAA submission planned for Q3 2025 – SKYTROFA Q3 revenue of €47.2 million – 60%+ year-over-year volume growth offset by current and prior period sales deductions – Full year 2024 SKYTROFA revenue excluding sales deductions related to prior years expected to be €200 - €220 million, and fu GlobeNewswire ? 8 days ago ASND +5.85% Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024 COPENHAGEN, Denmark, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report third quarter 2024 financial results and provide a business update on Thursday, November 14, 2024, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on November 14, 2024, at 4:30 p.m. Eastern Time (ET) to discuss its third quarter 2024 financial results. Those who would like to participate may access the live webca GlobeNewswire ? 15 days ago ASND +5.85% High Growth Tech Stocks In The United States To Watch The market has been flat over the last week but is up 31% over the past year, with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability while aligning with these positive market trends. Simply Wall St. ? 16 days ago ASND +5.85% MIRM ARQT Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA Ascendis Pharma will license its TransCon technology to Novo to develop therapies for metabolic and cardiovascular diseases. Pharmaceutical Technology ? 17 days ago NVO GLDAF ASND +5.85% Novo Nordisk Secures License for Ascendis Pharma's Obesity Drug Technology The main project is a once-monthly GLP-1 receptor agonist for obesity and type 2 diabetes GuruFocus.com ? 17 days ago NVO ASND +5.85% Ascendis Pharma and Novo Nordisk Join Forces Ascendis Pharma (ASND) has released an update. Ascendis Pharma has entered a collaboration with Novo Nordisk to license its TransCon technology, aiming to develop treatments for metabolic and cardiovascular diseases, including a monthly TransCon Semaglutide product for obesity and type 2 diabetes. The agreement could bring Ascendis up to $285 million in milestone payments, along with sales-based royalties. Novo Nordisk will handle the clinical development and commercialization, with Ascendis foc TipRanks ? 17 days ago ASND +5.85% Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform Ascendis Pharma (ASND) announced that it has granted Novo Nordisk (NVO) an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases and a product-by-product exclusive license in cardiovascular diseases. The agreement includes provisions requiring certain TransCon technology-based products to be identified and advanced in metabolic diseases to maintain exclusivity in the field and additional p TipRanks ? 17 days ago NONOF NVO ASND +5.85% Ozempic maker Novo Nordisk is working on a once-monthly weight-loss drug Novo Nordisk (NVO), the maker of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, has entered an agreement with Denmark-based Ascendis Pharma (ASND) to leverage the latter’s advanced drug delivery technology. Quartz ? 18 days ago NVO ASND +5.85% Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug On Monday, Ascendis Pharma A/S (NASDAQ:ASND) granted Novo Nordisk A/S (NYSE:NVO) an exclusive worldwide license. The pact will focus on the TransCon technology platform to develop, manufacture, and commercialize Novo Nordisk proprietary products for metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license for cardiovascular diseases. Also Read: Ascendis Pharma’s Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year The agre Benzinga ? 18 days ago NVO ASND +5.85% Ascendis, Novo Nordisk to Develop, Commercialize Products in Metabolic, Cardiovascular Diseases Ascendis, Novo Nordisk to Develop, Commercialize Products in Metabolic, Cardiovascular Diseases PREMIUM MT Newswires ? 18 days ago NVO ASND +5.85% Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases - Collaboration leverages Ascendis’ proprietary TransCon? technologies and Novo Nordisk’s expertise in cardiometabolic diseases - Once-monthly GLP-1 receptor agonist will be the collaboration’s lead product candidate COPENHAGEN, Denmark, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has granted Novo Nordisk A/S an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary produc GlobeNewswire ? 18 days ago ASND +5.85% Ascendis Pharma submits sBLA for growth hormone deficiency therapy The sBLA is backed by Phase III trial data, confirming the therapy’s safety and effectiveness. Pharmaceutical Technology ? last month ASND +5.85% High Growth Tech Stocks To Watch In October 2024 The market has been flat over the last week but is up 33% over the past year, with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these favorable conditions is crucial for investors looking to maximize their returns. Simply Wall St. ? last month CYBR LEGN +2.99% ASND +5.85% New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon? PTH (Palopegteriparatide) Presented at ASBMR 2024 COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) shared 3-year results from the Company’s ongoing Phase 2 PaTH Forward Trial of 57 adults with hypoparathyroidism showing that long-term treatment with TransCon? PTH (palopegteriparatide; marketed as YORVIPATH?) through Week 162 drove bone remodeling into the normal range. Deficiency of parathyroid hormone is associated with low rates of bone remodeling, accumulation of overly mature bone, and higher-than-a GlobeNewswire ? last month ASND +5.85% Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon? hGH for the Treatment of Adults with Growth Hormone Deficiency COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food & Drug Administration (FDA) for TransCon hGH (marketed as SKYTROFA? (lonapegsomatropin-tcgd) in the U.S. for pediatric growth hormone deficiency) for the treatment of adults with growth hormone deficiency (GHD). “The sBLA submission for TransCon hGH for adult GHD supports our strategy to develop SKYTROFA i GlobeNewswire ? last month ASND +5.85% BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish Last week, Ascendis Pharma A/S (NASDAQ:ASND) released topline data on Monday from a trial that included 84 children with achondroplasia, a genetic disorder that causes dwarfism and disproportionate short stature. Goldman Sachs hosted an investor meeting with BioMarin Pharmaceutical Inc's (NASDAQ:BMRN) Alexander Hardy (President and CEO) and Brian Mueller (EVP, CFO). They reiterated financial guidance after reviewing their assumptions around Voxzogo competition post-Ascendis Pharma's better-than- Benzinga ? last month BMRN ASND +5.85% Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs COPENHAGEN, Denmark, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the pricing of its underwritten public offering of 2,000,000 American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis, at a price to the public of $150.00 per ADS. All of the ADSs are being offered by Ascendis. The offering is expected to close on or about September 23, 2024, subject to the satisfaction of customary closing conditions. In addition, Ascend GlobeNewswire ? 2 months ago ASND +5.85% Ascendis Pharma A/S Announces Proposed Public Offering of ADSs COPENHAGEN, Denmark, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has commenced an underwritten public offering of $300,000,000 of American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis. All of the ADSs are being offered by Ascendis. In addition, Ascendis expects to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of ADSs at the public offering price, less the underwriting com GlobeNewswire ? 2 months ago ASND +5.85% Ascendis Soars on Encouraging Data From Dwarfism Drug Study ASND stock surges after data from a study shows that its investigational achondroplasia therapy achieved the primary study goal. Zacks ? 2 months ago ILMN BMRN BVS Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last? Ascendis Pharma (ASND) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term. Zacks ? 2 months ago ASND +5.85% ALEC Performance Overview Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is MSCI WORLD Return ASND MSCI WORLD YTD +3.06% +18.83% 1-Year +38.98% +25.54% 3-Year -12.77% 0.00%
